JO
BIO icon

John Overdeck’s Bio-Rad Laboratories Class A BIO Stock Holding History

John Overdeck’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,600
Closed -$8.01M – 2791
2021
Q4 		$8.01M Buy
10,600
+7,600
+253% +$5.69M 0.02% 915
2021
Q3 		$2.24M Buy
3,000
+1,600
+114% +$1.2M 0.01% 1884
2021
Q2 		$902K Buy
+1,400
New +$852K ﹤0.01% 2571

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

John Overdeck's BIO Position: Q2 2026 in Review

John Overdeck reduced its Bio-Rad Laboratories Class A (BIO) stake by 6.1% in Q2 2026, selling an estimated $189K and leaving 10,320 shares worth $3.03M. The position accounts for ﹤0.01% of the portfolio, ranked #2616.

John Overdeck first reported a position in BIO in Q2 2013 and has held it in 46 quarters since. The position peaked at $53.6M in Q3 2019. 396 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • John Overdeck held 10,320 shares of Bio-Rad Laboratories Class A worth $3.03M as of Q2 2026.
  • John Overdeck sold 668 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $189K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2616 holding.
  • John Overdeck first reported a position in Bio-Rad Laboratories Class A in Q2 2013 and has held it in 46 quarters since.
  • John Overdeck's Bio-Rad Laboratories Class A position peaked at $53.6M in Q3 2019.
  • 396 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.